Publications by authors named "Chi-Young Jung"
Article Synopsis
- The study investigates the effects of durvalumab consolidation therapy on patients with non-small cell lung cancer (NSCLC) who have either mutant (EGFR M+) or wild-type (EGFR M-) epidermal growth factor receptors, specifically looking at programmed death-ligand 1 (PD-L1) expression levels.
- Of the 249 unresectable stage III NSCLC patients treated, only 12.4% had EGFR M+, with the median progression-free survival (PFS) being significantly longer in patients with high PD-L1 expression (≥50%) compared to those with EGFR M+ and low PD-L1 expression.
- The findings suggest that durvalumab can be beneficial for EGFR M+
Article Synopsis
- Recent advances in treating resectable non-small cell lung cancer (NSCLC), particularly the ADAURA trial, highlight the effectiveness of osimertinib for patients at high risk of relapse, necessitating further studies to identify these specific subgroups.
- A study analyzing data from 3,176 NSCLC patients concluded that 14.0% experienced late recurrence, with the EGFR-mutant subgroup being particularly studied for relapse factors.
- Key factors influencing postoperative relapse in patients with EGFR mutations include age, pathologic N and TNM stages, pleural invasion status, and type of surgery, indicating that those with advanced conditions or specific surgical histories are at greater risk.
Article Synopsis
- The PACIFIC trial showed that durvalumab improves survival for certain lung cancer patients, but there’s limited data on its effectiveness in those aged 70 and older.
- A retrospective study analyzed 286 patients, revealing similar progression-free survival (PFS) and overall survival (OS) between elderly and younger groups, yet elderly patients had a lower completion rate of durvalumab.
- Elderly patients experienced more adverse events (AEs), especially pulmonary issues, suggesting the need for careful patient selection and monitoring when treating older patients with durvalumab.
Background: About 3%-5% of non-small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK-positive NSCLC. This study aimed to analyze the real-world efficacy and outcome when administered crizotinib, the first approved target agent for ALK-positive NSCLC, according to first- or late-line treatment.
View Article and Find Full Text PDFBackground: Data from clinical trials and real-world studies show that afatinib is effective in treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor () gene. A previous analysis of patients enrolled in the Korean Academy of Tuberculosis and Respiratory Disease (KATRD) cohort showed that first-line afatinib was well tolerated and effectiveness results were encouraging. At the time of the previous analysis, survival data were not mature.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to assess the impact of a new psychiatric intervention aimed at addressing acute stress and psychological difficulties in COVID-19 inpatients in Daegu, Korea.* -
- Out of 32 participants, 21 showed significant psychological distress, particularly those with a history of mental health issues, and received telepsychiatry consultations to help alleviate their problems.* -
- The findings indicated that the intervention was effective in improving overall emotional well-being, emphasizing the need for innovative psychological support methods in healthcare post-COVID-19.*
Background: This study aimed to establish nationwide data for the distributions of typical and atypical bacterial pathogens in Korean patients with moderate acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and evaluate the clinical usefulness of a urinary antigen test (UAT) to detect .
Methods: This study was a post hoc analysis of a randomized controlled trial designed to compare oral zabofloxacin with moxifloxacin for treating outpatients with moderate AECOPD. From clinics across South Korea, 342 subjects with AECOPD were enrolled, and their blood, sputum, and urine samples were collected at baseline.
Purpose: This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials And Methods: The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Article Synopsis
- The study emphasizes the importance of real world data (RWD) for understanding and responding to the COVID-19 pandemic using a standardized approach through the CHARYBDIS framework.
- Researchers conducted a retrospective database study across multiple countries, including the US and parts of Europe and Asia, involving over 4.5 million individuals and focusing on their clinical characteristics and outcomes.
- Findings reveal higher diagnoses among women but more hospitalizations among men, common comorbidities like diabetes and heart disease, and key symptoms such as cough and fever; this data helps to identify trends in COVID-19 across different populations and time periods.
Background: We investigated the clinical characteristics and treatment outcomes of Korean patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation-positive (m) non-small cell lung cancer (NSCLC) in a real-world setting.
Methods: Electronic case reports were retrospectively reviewed from patients across 15 sites in South Korea. Outcome measures included baseline characteristics, overall response rate (ORR), time-to-treatment discontinuation (TTD), and overall survival (OS).
Background: Chronic obstructive pulmonary disease (COPD) is considered a risk factor for poor outcomes in patients with coronavirus disease 2019 (COVID-19). However, data on the prognostic impact of radiological emphysema extent on patients with COVID-19 are limited. Thus, this study aimed to examine whether computed tomography (CT)-quantified emphysema score is associated with a worse clinical outcome in patients with COVID-19.
View Article and Find Full Text PDFRationale: Simultaneous occurrence of anti-glomerular basement membrane (anti-GBM) disease and thin basement membrane nephropathy (TBMN), both of which invade the type IV collagen subunits, is very rare. Here, we present the case of a 20-year-old male patient diagnosed with both anti-GBM disease and TBMN upon presenting dyspnea and hemoptysis.
Patient Concerns: No laboratory abnormalities, except arterial hypoxemia (PaO275.
Background: The impact of sarcopenia on clinical outcomes of coronavirus disease 2019 (COVID-19) is not clearly determined yet. We aimed to investigate the association between baseline sarcopenia and clinical outcomes in patients with COVID-19.
Methods: All hospitalized adult patients with COVID-19 who had baseline chest computed tomography (CT) scans at a Korean university hospital from February 2020 to May 2020 were included.
Article Synopsis
- Routinely collected real-world data (RWD) is essential for understanding and responding to the COVID-19 pandemic, as demonstrated by the CHARYBDIS framework for standardizing and analyzing this data.
- A descriptive cohort study involving over 4.5 million individuals was conducted across the U.S., Europe, and Asia to examine COVID-19-related health risks and outcomes, with detailed information available on an interactive website.
- The findings from the CHARYBDIS study serve as benchmarks to enhance our knowledge of COVID-19's progression and management, facilitating timely evaluations of new preventative and therapeutic strategies.
Background: In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR-tyrosine kinase inhibitors (TKIs). The aim was to identify the clinical impact of rebiopsy.
Methods: This multicenter, retrospective cohort study was conducted in South Korea from January 2007 to June 2017.
Experience of percutaneous tracheostomy in critically ill COVID-19 patients.
Acute Crit Care
November 2020
Background: Coronavirus disease 2019 (COVID-19) is a highly contagious disease that causes respiratory failure. Tracheostomy is an essential procedure in critically ill COVID-19 patients; however, it is an aerosol-generating technique and thus carries the risk of infection transmission. We report our experience with percutaneous tracheostomy and its safety in a real medical setting.
View Article and Find Full Text PDFBackgrounds: The present study evaluated Korean women with lung cancer and compared the clinical characteristics of ever-smoker and never-smoker groups using the National Lung Cancer Registry.
Methods: In affiliation with the Korean Central Cancer Registry, the Korean Association for Lung Cancer constructed a registry into which 10% of the lung cancer cases in Korea were registered. Female lung cancer patients with valid smoking history were evaluated.
Article Synopsis
- * A study analyzed 34,128 COVID-19 patients across the US, South Korea, and Spain, revealing differences in gender and age demographics among countries.
- * Compared to influenza patients hospitalized from 2014-2019, COVID-19 patients tend to be younger, more often male, and have fewer comorbidities and lower medication use, indicating a need for tailored response strategies.
Background: Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than eight million people worldwide by June 2020. Given the importance of the presence of diabetes mellitus (DM) for host immunity, we retrospectively evaluated the clinical characteristics and outcomes of moderate-to-severe COVID-19 in patients with diabetes.
Methods: We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease.
Background/aims: The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19). To compare the virological and clinical responses to lopinavir-ritonavir and hydroxychloroquine treatment in COVID-19 patients.
Methods: This retrospective cohort study included patients with COVID-19 treated with lopinavir-ritonavir or hydroxychloroquine at a single center in Korea from February 17 to March 31, 2020.
Background In this study we phenotyped individuals hospitalised with coronavirus disease 2019 (COVID-19) in depth, summarising entire medical histories, including medications, as captured in routinely collected data drawn from databases across three continents. We then compared individuals hospitalised with COVID-19 to those previously hospitalised with influenza. Methods We report demographics, previously recorded conditions and medication use of patients hospitalised with COVID-19 in the US (Columbia University Irving Medical Center [CUIMC], Premier Healthcare Database [PHD], UCHealth System Health Data Compass Database [UC HDC], and the Department of Veterans Affairs [VA OMOP]), in South Korea (Health Insurance Review & Assessment [HIRA]), and Spain (The Information System for Research in Primary Care [SIDIAP] and HM Hospitales [HM]).
View Article and Find Full Text PDFSerologic assays have been developed to detect infection with coronavirus disease 2019 (COVID-19). This study was conducted to evaluate the diagnostic performance of an immunochromatography-based assay of human serum for COVID-19. The present study enrolled 149 subjects who had been tested by real-time reverse transcription-polymerase chain reaction (RT-PCR) for COVID-19 and were classified into two groups: 70 who were positive for COVID-19 and 79 who were negative for COVID-19 based on RT-PCR.
View Article and Find Full Text PDFArticle Synopsis
- A study investigated the link between genetic variations in the Notch pathway and survival rates in patients with non-small cell lung cancer (NSCLC) who had surgery.
- Researchers analyzed 64 gene variants in a total of 1,872 patients across multiple studies, identifying 9 variants associated with survival.
- Specifically, the variant DTX1 rs1732786A>G was consistently associated with improved overall and disease-free survival, indicating its potential as a prognostic factor for NSCLC patients.
Purpose: The aim of this study was to investigate epidemiology, clinical characteristics and sex differences of patients with lung cancer using nationwide registry in Korea.
Materials And Methods: The Korean Association for Lung Cancer developed a registry in cooperation with the Korean Central Cancer Registry, and surveyed about 10% of lung cancer cases. For this first survey of cases diagnosed in 2014, cases were selected through a systematic sampling method.